伊弗梅克通过降低TGF-β和Syndecan-1表达来减轻甲基甲酸诱导的肝纤维化
Cengiz Dibekoğlu1, Kubilay Kemertaş2, Hatice Aygun3
1Department of General Surgery, Demiroğlu Bilim University, 34394 Istanbul, Turkey.
Medicina (Kaunas, Lithuania)
|June 27, 2025
概括
伊弗梅克丁在大鼠中显示出显著的肝脏保护作用,防止甲三甲酸诱导的肝损伤. 它减少了氧化应激,炎症和纤维化,这表明药物诱导的肝损伤治疗的潜力.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 甲托雷克萨特 (MTX) 是一种广泛使用的药物,与显著的肝毒性有关.
- MTX诱导的肝损伤包括氧化应激,炎症和纤维化.
- 需要有效的策略来缓解MTX相关的肝损伤.
研究的目的:
- 调查ivermectin对MTX诱导的肝损伤的肝保护潜力.
- 评估ivermectin对大鼠模型中肝损伤的生化和组织病理标志物的影响.
主要方法:
- 三十只雄性威斯塔尔白色老鼠被分为对照组,只有MTX的和MTX+ivermectin的组.
- MTX是用腹膜内注射的,随后是口服ivermectin治疗.
- 肝脏组织和血分析了ALT,MDA,TGF-β和syndecan-1水平,以及他的病理学.
主要成果:
- MTX显著增加了血和肝脏的MDA,TGF-β,syndecan-1和ALT水平,导致,纤维化和炎症.
- 艾弗梅克丁治疗显著降低了这些升高的标志物,改善了肝脏组织学.
- 组织学评分显示,在ivermectin组中,缩,纤维化和炎症细胞透率下降.
结论:
- 艾弗梅克丁对MTX诱导的肝损伤具有显著的肝保护作用.
- 保护机制可能涉及抗氧化,抗炎,抗纤维和内皮保护.
- 艾弗梅克显示出对重新利用来管理药物诱导的肝损伤的承诺.
更多相关视频
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
5.7K
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.4K
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243
01:27Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208